Immunocore is a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, infectious and autoimmune. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. Immunocore’s most advanced oncology therapeutic candidate, tebentafusp, has demonstrated an overall survival benefit in a randomized Phase 3 clinical trial in metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies.
| Market Cap | 1.433 Billion | Shares Outstanding | 43.786 Million | Avg 30-day Volume | 62.456 Thousand | ||
| P/E Ratio | Dividend Yield | EPS | |||||
| Price/Sales | Debt to Equity | EBITDA | |||||
| Price to Book Value | 0.0 | Forward PE | Enterprise Value | ||||
| Total Cash | Current Debt | Gross Profit | |||||
| BETA | 0.0 | 52-week High/Low | 61.99 / 30.92 | Next Earnings Date | 2021-08-11 | Price to Cash FLow (P/CF) | -9999999.0 |
| Data provided by IEX Cloud | |||||||
| Q1 2021 | All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|---|---|---|---|---|---|
| In top 10: | 3 | 0 | 1 (0.06%) | No data | ||
| Funds Holding: | 41 | 0 | 22 (1.29%) | No data | ||
| 13F shares: | 15.164 Million | 0 | 8.372 Million | No data | ||
| % Ownership | 34.6324 | 19.1207 | No data | |||
| New Positions: | 40 | 22 | No data | |||
| Increased Positions | No data | |||||
| Closed Positions | No data | |||||
| Reduced Positions | No data | |||||
| Total Calls | No data | |||||
| Total Puts | No data | |||||
| PUT/CALL Ratio | No data | No data | ||||
| 1 hedge funds and active managers as identified by whalewisdom.com through public filings. | ||||||
Please sign in first
none
none
none
| Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
|---|
| Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No current insider transactions | ||||||||||||||||
* -
| Code | Definition |
|---|---|
| A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
| C | Conversion of derivative security |
| D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
| G | Bona fide gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
| J | Other acquisition or disposition |
| L | Small acquisition under Rule 16a-6 |
| M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
| O | Exercise of out-of-the-money derivative security |
| P | Open market or private purchase of non-derivative or derivative security |
| S | Open market or private sale of non-derivative or derivative security |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| W | Acquisition or disposition by will or the laws of descent and distribution |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
| Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
|---|---|---|---|---|
| IMMUNOCORE HOLDINGS PLC-ADR IMCR | 2021-08-02 22:15:03 UTC | -0.3559 | 0.4159 | 4000 |
| IMMUNOCORE HOLDINGS PLC-ADR IMCR | 2021-08-02 21:45:03 UTC | -0.3559 | 0.4159 | 4000 |
| IMMUNOCORE HOLDINGS PLC-ADR IMCR | 2021-08-02 21:15:03 UTC | -0.3559 | 0.4159 | 4000 |
| IMMUNOCORE HOLDINGS PLC-ADR IMCR | 2021-08-02 20:45:03 UTC | -0.3559 | 0.4159 | 4000 |
| IMMUNOCORE HOLDINGS PLC-ADR IMCR | 2021-08-02 20:15:03 UTC | -0.3559 | 0.4159 | 4000 |
| IMMUNOCORE HOLDINGS PLC-ADR IMCR | 2021-08-02 19:45:03 UTC | -0.3559 | 0.4159 | 4000 |
| IMMUNOCORE HOLDINGS PLC-ADR IMCR | 2021-08-02 19:15:03 UTC | -0.3559 | 0.4159 | 4000 |
| IMMUNOCORE HOLDINGS PLC-ADR IMCR | 2021-08-02 18:45:03 UTC | -0.3559 | 0.4159 | 4000 |
| IMMUNOCORE HOLDINGS PLC-ADR IMCR | 2021-08-02 18:15:03 UTC | -0.3559 | 0.4159 | 4000 |
| IMMUNOCORE HOLDINGS PLC-ADR IMCR | 2021-08-02 17:45:03 UTC | -0.3559 | 0.4159 | 4000 |
| IMMUNOCORE HOLDINGS PLC-ADR IMCR | 2021-08-02 17:15:03 UTC | -0.3559 | 0.4159 | 4000 |
| IMMUNOCORE HOLDINGS PLC-ADR IMCR | 2021-08-02 16:45:03 UTC | -0.3576 | 0.4376 | 4000 |
| IMMUNOCORE HOLDINGS PLC-ADR IMCR | 2021-08-02 16:15:03 UTC | -0.3576 | 0.4376 | 4000 |
| IMMUNOCORE HOLDINGS PLC-ADR IMCR | 2021-08-02 15:45:03 UTC | -0.3576 | 0.4376 | 4000 |
| IMMUNOCORE HOLDINGS PLC-ADR IMCR | 2021-08-02 15:15:03 UTC | -0.3576 | 0.4376 | 4000 |
| IMMUNOCORE HOLDINGS PLC-ADR IMCR | 2021-08-02 14:45:03 UTC | -0.3578 | 0.4378 | 4000 |
| IMMUNOCORE HOLDINGS PLC-ADR IMCR | 2021-08-02 14:15:03 UTC | -0.3578 | 0.4378 | 4000 |
| IMMUNOCORE HOLDINGS PLC-ADR IMCR | 2021-08-02 13:45:03 UTC | -0.3578 | 0.4378 | 4000 |
| IMMUNOCORE HOLDINGS PLC-ADR IMCR | 2021-08-02 13:15:04 UTC | -0.3578 | 0.4378 | 4000 |
| IMMUNOCORE HOLDINGS PLC-ADR IMCR | 2021-08-02 12:45:03 UTC | -0.3578 | 0.4378 | 4000 |
| Holder | Issuer | Net Short Position | Position Date | Origin |
|---|---|---|---|---|
| Series Portfolios Trust- Weiss Alternative Balanced Risk Fund | IMCR | -32.0 shares, $-1291.52 | 2021-04-30 | N-PORT |
